ClinicalTrials.gg
Sign In
RecruitingNCT00669266Updated May 7, 2026

Adrenal Tumors - Pathogenesis and Therapy

An observational study in Adrenal Tumors, Adrenocortical Carcinoma and Cushing Syndrome, sponsored by University of Wuerzburg. Recruiting at 1 site in Germany. Open to participants aged Up to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Primary conditionAdrenocortical CarcinomaRegistry: Adrenal Gland NeoplasmsReclassifiedWhy we changed it
Registry
Adrenal Gland Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Adrenocortical Carcinoma
Why
  1. The study's listed conditions name Adrenocortical Carcinoma, a narrower term within Adrenal Gland Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Wuerzburg · Observational

From the registry’s dates

  • Started Sep 2002; still recruiting 24 years 2 months later.
Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
500
Ages
Up to 100 Years
Sex
All
01

Study summary

The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.

02

Conditions studied

  • Adrenal Tumors
  • Adrenocortical Carcinoma
  • Cushing Syndrome
  • Conn Syndrome
  • Pheochromocytoma
03

In context

Adrenocortical Carcinoma Reclassified

94 studies on the registry are indexed under Adrenocortical Carcinoma; 26 are open to participants now.

This study's planned enrollment of 500 is above the median of 100 across 19 observational studies indexed under Adrenocortical Carcinoma.

Browse Adrenocortical Carcinoma studies →

Lead sponsor

University of Wuerzburg is the lead sponsor of 32 studies on the registry; 3 are open to participants now.

Compared within Adrenocortical Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Adrenal Gland Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Up to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with adrenal tumors

Inclusion criteria

  • adrenal tumor detected by imaging

Exclusion criteria

Exclusion Criteria:

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
500 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Tumor

    Tumor material and corresponding biosamples from patients with adrenal tumors

  • control group

    Biomaterial from patients without adrenal tumor

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Tamburello M, Altieri B, Sbiera I, Sigala S, Berruti A, Fassnacht M, Sbiera S. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine. 2022 Sep;77(3):411-418. doi: 10.1007/s12020-022-03074-z. Epub 2022 May 18. PubMed 35583844 ↗
  • Sbiera I, Kircher S, Altieri B, Lenz K, Hantel C, Fassnacht M, Sbiera S, Kroiss M. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Front Endocrinol (Lausanne). 2021 Dec 9;12:795116. doi: 10.3389/fendo.2021.795116. eCollection 2021. PubMed 34956100 ↗
  • Weigand I, Ronchi CL, Vanselow JT, Bathon K, Lenz K, Herterich S, Schlosser A, Kroiss M, Fassnacht M, Calebiro D, Sbiera S. PKA Calpha subunit mutation triggers caspase-dependent RIIbeta subunit degradation via Ser114 phosphorylation. Sci Adv. 2021 Feb 19;7(8):eabd4176. doi: 10.1126/sciadv.abd4176. Print 2021 Feb. PubMed 33608270 ↗
  • Weigand I, Schreiner J, Rohrig F, Sun N, Landwehr LS, Urlaub H, Kendl S, Kiseljak-Vassiliades K, Wierman ME, Angeli JPF, Walch A, Sbiera S, Fassnacht M, Kroiss M. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis. 2020 Mar 17;11(3):192. doi: 10.1038/s41419-020-2385-4. PubMed 32184394 ↗
  • Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assie G, Weigand I, Calebiro D, Schwarzmayr T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK, Mantero F, Mannelli M, Kastelan D, Chiodini I, Bertherat J, Reincke M, Strom TM, Fassnacht M, Beuschlein F; European Network for the Study of Adrenocortical Tumors (ENSAT). Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. J Clin Endocrinol Metab. 2016 Sep;101(9):3526-38. doi: 10.1210/jc.2016-1586. Epub 2016 Jul 7. PubMed 27389594 ↗
  • Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med. 2014 Mar 13;370(11):1019-28. doi: 10.1056/NEJMoa1310359. Epub 2014 Feb 26. PubMed 24571724 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00669266
Lead sponsor
University of Wuerzburg
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany), German Federal Ministry of Education and Research
Responsible party
Martin Fassnacht (Head of Endocrinology, University of Wuerzburg) — Principal investigator
First posted
Apr 30, 2008
Start date
Sep 2002
Primary completion
Dec 2030 (estimated)
Completion
Dec 2032 (estimated)
Last update
May 7, 2026

Study contacts

Martin Fassnacht, MD
Contact
fassnacht_m@medizin.uni-wuerzburg.de
49-931-201-36507
Martin Fassnacht, MD
principal investigator · U of Wuerzburg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Adrenocortical Carcinoma →

Other studies from this sponsor

University of Wuerzburg

Start the discussion